The optimal measure of vitamin D status is unknown. Results: Free 25(OH)D was 4.7 6 1.8 pg/mL (mean 6 SD) in healthy persons and 4.3 6 1.9 pg/mL in outpatients, with levels of 0.5 to 8.1 pg/mL and 0.9 to 8.1 pg/mL encompassing 95% of healthy persons and outpatients, respectively. Free 25(OH)D was higher in patients with cirrhosis (7.1 6 3.0 pg/mL; P , 0.0033) and nursing home residents (7.9 6 2.1 pg/mL; P , 0.0033) than in other 
groups and differed between whites and blacks (P , 0.0033) and between DBP haplotypes (P , 0.0001). Mixed-effects modeling of relationships between free and total 25(OH)D identified clinical conditions (patients with cirrhosis . nursing home residents . patients with prediabetes . outpatients . pregnant women) and BMI (lesser effect) as covariates affecting relationships but not eGFR, sex, race, or DBP haplotype. (4) (5) (6) (7) . Altered albumin concentrations, such as the lower levels reported in the frail elderly or nursing home residents (8) , could also alter free 25(OH)D concentrations, albeit to a smaller extent than changes in DBP. Thus, total 25(OH)D may not accurately reflect levels available for cellular uptake, with the exception of cells in the kidney or parathyroid capable of megalin/cubilinmediated internalization of DBP-bound 25(OH)D (9) .
The goal of this work was to combine data from human investigations involving direct measurement of free 25(OH)D to address two objectives. The first is to describe the distribution of circulating free 25(OH)D concentrations in adult humans with and without various conditions or disease states known to alter DBP, in people with differing DBP haplotypes that might alter DBP levels or binding, in people with a wide range of body weights because higher body mass indexes (BMIs) seen with obesity, metabolic syndrome, or prediabetes alter total 25(OH)D and calculated free 25(OH)D (10) and in groups for which no data on free 25(OH)D are currently available such as the very elderly, nursing home residents, and women with osteoporosis who are likely to receive D supplementation or receive exogenous female sex hormones. The second objective is to determine relationships between free and total 25(OH)D in these clinical conditions and disease states and among different DBP haplotypes. Our findings provide a measure of the normal range of free 25(OH)D concentrations as well as observations on factors that do and do not alter relationships between free and total 25(OH)D in clinical populations.
Participants and Methods

Participants
Investigators who directly measured free 25(OH)D in clinical investigations contributed de-identified data. Adult groups sampled included healthy persons, medically stable communitydwelling outpatients enrolled in longitudinal or D dosing studies, persons with prediabetes, medically stable nursing home residents over age 65 years, stable patients with cirrhosis, and pregnant women (second or third trimester) (2, (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) . Participants provided informed consent for the research, which was approved by the institutional review board of the respective organizations. For investigators, sites, and participant descriptions see the Supplemental Material.
Laboratory measurements
Free 25(OH)D levels
Direct measurement of free 25(OH)D concentrations was by immunoassay (Future Diagnostics B.V., Wijchen, Netherlands) as described (23) . In brief, an antibody to 25(OH)D is precoated onto a microtiterplate and serum samples and calibrators added. Free 25(OH)D is captured during this first incubation step, and after washing, a second incubation with biotin-labeled 25(OH)D analog reacts with nonoccupied antibody binding sites (competitive immunoassay). Finally, after washing and incubating with a streptavidin-peroxidase conjugate, absorbance (A450 nm) is measured by using a plate spectrophotometer, where concentration of free 25(OH)D in the sample is inversely proportional to absorbance in each sample well. Assay calibration was against a symmetric dialysis method. Limit of detection for blank serum is 0.7 pg/mL; at 5.02 pg/mL, betweenrun coefficient of variation (CV) was 6.2% and between-day CV was 4.5%, with a total imprecision CV of 15.7%. Biotin at 4 mg/dL of free 25(OH)D was tested for assay interference and mean percentage interference was 1% at 6.5 pg/mL, 4% at 10.6 pg/mL, and 1% at 15.7 pg/mL. Assays were performed at Future Diagnostics B.V. except for measurements in patients with prediabetes, which were performed in Tromsø using the Future Diagnostics B.V. kit (Wijchen, Netherlands) with the same technique calibrated over the range of 0.1 to 35 pg/mL with a limit of detection of 2.8 pg/mL; inter-and intra-assay CVs were , 10% (24). 
Total 25(OH)D
Data analysis
Demographic, clinical characteristics, and assay results are presented as mean 6 SD. ANOVA for trends followed by post hoc analyses for between-group comparisons using Bonferroni correction for multiple comparisons was used to test for differences in total, free, or percentage free 25(OH)D between clinical groups, DBP haplotypes, or self-reported racial groups. Relationships between free and total 25(OH)D were examined by using a mixed-effects model incorporating clinical condition and DBP haplotypes with sex, race, estimated glomerular filtration rate (eGFR), BMI, and other biologically plausible covariates and interactions. Relationships between free or total 25(OH)D and iPTH were examined in the same manner, including iPTH assay method as a covariate. Analyses were performed in R (R Foundation for Statistical Computing, Vienna, Austria). The fixed-effect part of the model takes the following form: free = a + (b + c COV)total, where a is the intercept, b is the slope of the relationship free vs total, and c is a vector of parameters quantifying the relationship of the slope with covariates. Slopes are assumed to be normally distributed across individuals. Model selection was conducted by using standard procedures according to the Akaike criterion (27) and visual inspection of diagnostic plots. After model selection, comparisons to the reference group were computed according to a two-sided t test using the Satterthwaite approximation (R lmerTest). Exploratory analyses of effects of sex hormones in women were performed by using linear regression.
Results
Participant data
Data were from 1661 participants. Demographic characteristics by clinical group (healthy, prediabetic, communitydwelling outpatient, cirrhotic, pregnant, nursing home resident), eGFR, albumin, calcium, albumin-corrected calcium, DBP, total and free 25(OH)D, and iPTH are listed in Table 1 Table 1 ). The highest mean free 25(OH)D was in nursing home residents, accompanied by higher total 25(OH)D and lower DBP than in healthy persons, outpatients, patients with prediabetes, and pregnant women, but higher DBP than in patients with cirrhosis (P , 0.0033). The next highest mean free 25(OH)D was in patients with cirrhosis (higher than in healthy persons, pregnant women, patients with prediabetes, and outpatients (post hoc P , 0.0033 for all comparisons). Between-group differences were detected for all comparisons (post hoc P , 0.0033) except for healthy persons vs pregnant women or outpatients, and for pregnant women vs outpatients. Both DBP and total 25(OH)D were lowest in patients with cirrhosis. Pregnant women had the second highest total 25(OH)D levels and the highest DBP (post hoc P , 0.0033), despite measurement by a less sensitive assay. Albumin concentrations were not correlated with DBP (r 2 = 0.0004; P = 0.83) in the absence of pregnancy or cirrhosis. Percentage free 25(OH)D was higher in patients with cirrhosis and nursing home residents than in other clinical groups (post hoc P , 0.0033), and between-group comparisons were significant for all but healthy persons compared with pregnant or outpatients and for pregnant women vs outpatients.
Effects of race and DBP haplotype
Genotype data were available for 959 participants (outpatients, patients with prediabetes, and healthy persons; Table 2 ). Ninety-eight were of self-reported b Assays performed at Future Diagnostics BV, except for in patients with prediabetes; in those patients, assays were performed by using the same method at the investigator site. c Significant effect of clinical group (ANOVA, P , 0.0001).
d Post hoc between-group comparisons were significant at P , 0.0033 for all but healthy persons vs pregnant women or outpatients and for pregnant women vs outpatients. « Multiple samples of total and free 25(OH)D from some individuals from dose titrations studies.
f Assays were by liquid chromatography/tandem mass spectrometry except in 69 (of 90) patients with cirrhosis; in those patients, the LIAISON assay (DiaSorin) was used, and values were corrected by a calibration factor provided by the manufacturer. g Post hoc between-group comparisons were significant at P , 0.0033 for all but healthy persons vs outpatients, pregnant women, or patients with cirrhosis and for pregnant women vs outpatients or patients with prediabetes. h Post hoc between-group comparisons were significant at P , 0.0033 for all but healthy persons compared with pregnant women or outpatients and for pregnant women vs outpatients. i Post hoc between-group comparisons were significant at P , 0.0033 for all but healthy persons vs outpatients or patients with prediabetes and for patients with prediabetes vs outpatients. j DBP measurements by radial immunodiffusion assay (Leuven) except for pregnant women; in that group, DBP was determined by R&D assay (last column).
black race, 860 were white, and 1 was of self-reported other race. Differences in free 25(OH)D between whites and blacks were detected (4.9 6 1.9 vs 4.0 61.5 pg/mL, respectively; P , 0.0033). As expected, the 1f allele was more common in blacks and the 1s allele more common in whites. (Table 2 DBP levels were higher for the 1s/1s haplotype compared with any haplotype with at least one Gc2 allele (P , 0.0033) but not when compared with haplotypes 1s/1f or1f/1f. DBP levels were significantly lower for haplotype 2/2 than for 1f/2,1f/1f, and 1s/1f (P , 0.0033). No differences were detected between haplotypes 1s/1s vs 1s/1f or 1f/1f; 1s/2 vs 1f/2, 1s/2 vs 1f/1f, or 1s/1f vs 1f/1f. Differences between haplotypes 1s/1f vs 1f/2 approached significance (P = 0.0045) but failed to reach the post hoc criteria for significance (P , 0.0033).
Relationships between free and total 25(OH)D Individual data are plotted by clinical group and DBP haplotype in Fig. 3 . Linear mixed-effects modeling identified significant contributors to the relationship as the clinical condition and BMI. (see Table 3 ). Rejected covariates included eGFR and race. Clinically healthy persons were associated with the baseline slope (b) of the model. The steepest slope (b + 0.1577) was in patients with cirrhosis with the lowest DBP, the second steepest slope was in nursing home residents with the second lowest DBP levels, and the least steep slope was in pregnant women with the highest DBP. After exclusion of cirrhosis and pregnancy from the model, sex was selected for inclusion (male sex with coefficient estimate of 0.03 6 0.004). Effects of DBP haplotype on the relationship between free and total 25(OH)D were not detected in participants (n = 959) with these data.
Relationships between free and total 25(OH)D and iPTH
Both total and free 25(OH)D concentrations were negatively related to iPTH levels, but the mixed-effects model fits favored total 25(OH)D (coefficient estimate of 20.96 6 0.51). Covariates selected included BMI (continuous variable), with a small effect (0.02 6 0.004), and iPTH assay method, which varied within the sites; this precluded further clinical group analyses.
Exploratory analyses: female sex hormones
Forty young nonpregnant and noncirrhotic women reported taking oral contraceptives. Total and free 25(OH)D levels were 21.0 6 13.1 ng/mL and 3.4 6 2.2 pg/mL, respectively; these did not differ from the total and free 
Discussion
There is currently debate about the best serum measurement to determine vitamin D status (4). Circulating levels of 25(OH)D are the most commonly used marker a Significant differences in frequencies of haplotypes between the races for all haplotypes except for Gc1s/1f were detected.
b Statistically significant effects of DBP haplotype were detected for total, free, and percentage free 25(OH)D concentrations and DBP (ANOVA, P , 0.0001; see Fig. 2 and text for individual between-haplotype post hoc comparisons). Post hoc betweengroup comparisons were significant for all but healthy persons compared with pregnant women or outpatients, or for pregnant women compared with outpatients. For DBP haplotypes, smaller but significant differences were detected between the 1s/1s haplotype and the 1s/1f, 1f/2, 1f/1f, and 1s/2 haplotypes and between the 1s/2 and 1f/2 and 1f/1f haplotypes and between the 1s/1f and 1f/1f haplotypes. NH, nursing home.
for several reasons: (1) The concentration in blood is higher than that of other D metabolites, making it easier to measure; (2) The current study compiled data from an international working group of vitamin D investigators in order to describe free 25(OH)D concentrations in a wide range of people with various clinical conditions. The data were from healthy young and older people, people with prediabetes, community-dwelling outpatients enrolled in longitudinal studies or vitamin D studies, preand postmenopausal women with low vitamin D status, . DBP haplotype data were from healthy persons, community-dwelling outpatients, and patients with prediabetes. Linear mixed modeling detected significant effects of clinical groupings on the relationship between free and total 25(OH) D. *P , 0.05, **P , 0.0001, ***P , 0.000001 for comparisons with healthy persons. Significant effects of DBP haplotype on the relationship were not detected. ns, not significant. The mixed-effect model takes the form free = a + (b +c COV)total, where a is the intercept, b is the slope of the relationship free vs total 25(OH)D, and c is a vector of parameters quantifying the relationship of the slope with covariates. Variables tested but not selected included eGFR and race. Sex was not tested in this model. The t and P values represent comparisons to the baseline slope of the model (healthy persons).
pregnant women, patients with cirrhosis, and nursing home residents with multiple morbidities enrolled in observational or vitamin D studies. A major strength is that our international data represent the largest and most diverse sample of adults studied to date and included patients with conditions that alter both free 25(OH)D levels and the relationship between free and total 25(OH)D, groups for whom these data have not been previously available. Importantly, 98% of DBP measures were performed with one polyclonal method at one laboratory, and 95.8% of 25(OH)D measures were performed by laboratories participating in quality standardization programs (National Institute of Standards and Technology or Vitamin D External Quality Assessment Scheme) and 100% of free 25(OH)D measurements were performed using the same method. A strict definition of healthy persons was used to identify people with normal laboratory chemistry test results, no known chronic medical diseases, and no longterm oral medications except for thyroid or hormone replacement therapy, oral contraceptives, or dietary supplements. In these individuals, the mean concentration of free 25(OH)D was 4.3 6 1.9 pg/mL when mean total 25(OH)D concentration was 21.9 69.9 ng/mL. A range from 0.5 to 8.1 pg/mL included 95% of healthy participants and was similar to the 0.9-to-8.1 pg/mL range encompassing 95% of the stable outpatients (a group that was nearly three times larger). Mean free and total 25(OH)D concentrations as well as percentage free 25(OH)D were slightly higher in patients with prediabetes, yet the upper bound of the 95% CI was similar at 8.9 pg/mL. Free 25(OH)D in patients with prediabetes was measured by using the same technique but at a different site than all other assays. Some assay variation may explain the small differences; some patients with diabetes were included in the outpatient samples and did not show higher free or percentage free 25(OH)D (data not shown).
In our prior observations in pregnant women and a subset of patients with cirrhosis, DBP was measured by using a monoclonal antibody DBP assay (1-3, 23 ). In the current analyses, a polyclonal antibody was used in the radial immunodiffusion assay, which was performed at the same laboratory for all groups with the exception of the pregnant women. The data on the current larger group of patients with cirrhosis are consistent with early reports of lower DBP with higher directly measured mean free 25(OH)D despite lower total 25 (OH)D levels (10) . The data from pregnant women mirror the almost twofold higher DBP initially reported in pregnant women in the second and third trimesters compared with nonpregnant women (29, 30) and with less variability in free 25(OH)D. Although the group of pregnant women was small, similar mean free 25(OH)D with lesser variability than in other groups has been reproduced by using the same method in a larger group of about 300 white women, despite somewhat higher DBP in the second and third trimesters when measured by ELISA with a polyclonal antibody (31) .
We had limited data on women reporting oral contraceptive use or hormone replacement therapy with estrogen, but free 25(OH)D levels and relationships between total and free 25(OH)D did not appear to be significantly influenced by use of these agents at currently prescribed dosages and routes of administration.
An unexpected observation was that mean free 25(OH)D was higher in the nursing home residents, with distribution of values shifted toward higher concentrations. Likely contributors were both the lower DBP levels and the higher total 25(OH)D in the nursing home residents compared with the healthy persons, patients with prediabetes, community-dwelling outpatients, and pregnant women. Mean albumin concentrations were slightly lower in the nursing home residents than in the healthy persons, outpatients, or patients with prediabetes; however, because only 12% to 15% of 25(OH)D is bound to albumin, it is unlikely to have been a major factor. Inflammation and/or elevated cytokines that accompany very old age (32) or multiple morbidities could also alter affinity of 25(OH)D to DBP. Whatever the underlying mechanisms, both percentage free 25(OH)D concentrations and the relationship between free and total 25(OH)D differ in pregnant women, people with cirrhosis, and elderly people with multiple morbidities compared with healthy persons or community-dwelling outpatients; relationships are affected by BMI to a much smaller extent in all groups. It also appears that stable medical conditions, such as hypertension, prediabetes, diabetes, osteoporosis, or mild renal disease, do not appear to significantly alter relationships between free and total 25(OH)D.
Free 25(OH)D concentrations are related to total 25(OH)D concentrations as well as albumin and DBP and their binding affinities for 25(OH)D (29) . DBP is a highly polymorphic protein (33) . Our sample included whites and blacks and several Asians, and distribution of DBP haplotypes mirrored reported racial differences in that black (and Chinese) populations are more likely to carry the Gc1f allele and whites more likely to possess the Gc1s and the less frequent Gc2 allele (34) . DBP haplotype affected DBP and both total and free 25(OH)D concentrations. The Gc2/2 haplotypes and presence of 1f alleles were associated with lower total 25(OH)D concentrations as previously reported (35) . Gc1f has been reported to have the highest affinity and Gc2 the lowest affinity for vitamin D and its metabolites, but this has not been uniformly detected (7, 33, 36, 37 This study has limitations. Data were not from random population-wide samples, and analyses of BMI, sex, race, or other subgroup effects might not be representative of all populations. Samples were from medically stable individuals and may not apply to acute medical conditions. The only potential biomarker for vitamin D status analyzed was iPTH, and differing methods in clinical laboratories limited our analyses. However, the parathyroid gland has the megalin/ cubilin mechanism for cellular uptake of DBP, so parathyroid hormone levels are unlikely to discriminate between free and total 25(OH)D effects on biological function. Bone biomarkers were not assessed. Bone density has been reported to correlate better with measures of free than total 25(OH)D in the patients with prediabetes included in the current analyses (19) , but others have found similar relations between markers of bone metabolism and free or total 25(OH)D (38) . However, D and bone relationships are somewhat difficult to interpret because measures of vitamin D and its metabolites are often done only at a single timepoint, whereas bone density is the result of cumulative time effects. Because many participants sampled received D supplementation, we could not address seasonal effects.
Conclusions
Free 25(OH)D concentrations are affected by health conditions in addition to total 25(OH)D concentrations and DBP haplotype. Free 25(OH)D distributions were similar in healthy individuals and stable communitydwelling outpatients, with 95% within the range of 0.5 to 8.1 pg/mL and 0.9 to 8.1 pg/mL, respectively. Percentage free 25(OH)D was affected by clinical condition (patients with cirrhosis . nursing home residents . outpatients . healthy persons . pregnant women), self-reported race (black . white . Asian), and DBP haplotype (1f/1f + 1f/2 . 1f/1s, 2/2, 1s/2 . 1s/1s). Relationships between free and total 25(OH)D were influenced to a small extent by BMI and to a larger extent by health conditions; patients with cirrhosis and nursing home residents had the steepest slopes and pregnant women had the least steep slopes, without significant effects of DBP haplotype detected in mixedeffects models. Clinical outcomes data other than PTH levels are needed to determine the role of free 25(OH)D measurements in clinical decision-making, with the growing recognition of the role of vitamin D and its metabolites in promoting optimal health beyond bone and calcium absorption metabolism (39) . Currently, most vitamin D intake recommendations are based on immunoassay-measured total 25(OH)D levels associated with lower risk for osteoporotic fractures in postmenopausal women (40) .
As of May 30, 2018, ClinicalTrials.gov lists .600 completed phase 2, 3, and 4 trials of vitamin D relationships to various health conditions, 59 trials that are active and not recruiting, 149 trials that are currently recruiting, and 36 that are in the planning stages. Results from two very large randomized double-blind trials investigating vitamin D supplementation effects on cancer, cardiovascular disease, and mortality [VITAL (NCT01169259) and VIDAL (ISRCTN46328341)] will soon be available and will provide data on relationships with total 25(OH)D. However, to the extent that the free hormone hypothesis applies to cellular availability of vitamin D metabolites, total 25(OH)D measurements may be misleading in persons with altered total-to-free relationships, and analysis of free 25(OH)D could provide further insights.
